Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

被引:198
|
作者
Torres, Vicente E. [1 ]
Harris, Peter C. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
来源
关键词
PROTEIN-KINASE-A; LAMININ-BINDING INTEGRINS; LONG-ACTING SOMATOSTATIN; CYST EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; CYCLIC-AMP; RECEPTOR SUBTYPES; LIVER-DISEASE; IN-VITRO; PKD1; HAPLOINSUFFICIENCY;
D O I
10.1681/ASN.2013040398
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.
引用
收藏
页码:18 / 32
页数:15
相关论文
共 50 条
  • [1] Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
    Devuyst, Olivier
    Torres, Vicente E.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (04): : 459 - 470
  • [2] Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
    Zhou, Xia
    Torres, Vicente E.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [3] Targeting and therapeutic peptide-based strategies for polycystic kidney disease
    Wang, Jonathan
    Tripathy, Nirmalya
    Chung, Eun Ji
    ADVANCED DRUG DELIVERY REVIEWS, 2020, 161 : 176 - 189
  • [4] Polycystic Liver Disease: The Benefits of Targeting cAMP
    Larusso, Nicholas F.
    Masyuk, Tatyana V.
    Hogan, Marie C.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (07) : 1031 - 1034
  • [5] Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment
    Ma, Jingyi
    Staler, Dalton W.
    Mahato, Ram I.
    MEDICINAL CHEMISTRY RESEARCH, 2024, 33 (08) : 1339 - 1353
  • [6] Targeting B-Raf as a treatment strategy for polycystic kidney disease
    Sas, Kelli M.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2010, 299 (05) : F942 - F943
  • [7] Wnt signaling in polycystic kidney disease
    Benzing, Thomas
    Simons, Matias
    Walz, Gerd
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05): : 1389 - 1398
  • [8] mTOR signaling in polycystic kidney disease
    Ibraghimov-Beskrovnaya, Oxana
    Natoli, Thomas A.
    TRENDS IN MOLECULAR MEDICINE, 2011, 17 (11) : 625 - 633
  • [9] STAT signaling in polycystic kidney disease
    Strubl, Sebastian
    Torres, Jacob A.
    Spindt, Alison K.
    Pellegrini, Hannah
    Liebau, Max C.
    Weimbs, Thomas
    CELLULAR SIGNALLING, 2020, 72
  • [10] Calcium signaling in polycystic kidney disease
    Ehrlich, Barbara E.
    JOURNAL OF GENERAL PHYSIOLOGY, 2008, 132 (01): : 25A - 25A